Skip to main content
. 2017 Jul 14;17:226. doi: 10.1186/s12884-017-1415-4

Table 3.

Performance of various screening strategies

Sensitivity
TP/(TP + FN)
95% CI
Specificity
TN/(TN + FP)
95% CI
Negative Predictive Value
TN/(TN + FN)
Negative likelihood ratio
Point estimate
95% CI
Positive Predictive Value
TP/(TP + FP)
Positive likelihood ratio
Point estimate
95% CI
Venous 75 g OGTTa 1
18/(18 + 0)
(0.82–1)
1
598/(598 + 0)
(0.99–1)
1
598/(598 + 0)
n/a 1 (18/18 + 0) n/a
POC RBG ≥ 7 mmol/L (126.0 mg/dL) 0.17
3/(3 + 15)
(0.06–0.39)
0.97
581/(581 + 17)
(0. 95–98)
0.97
581/(581 + 15)
0.86
(0.70–1.1)
0.15
3/(3 + 17)
5.86
(1.89–18.23)
POC 1 h 50 g ≥ 7.8 mmol/L (140.4 mg/dL) 0.44
8/(8 + 10)
(0.25–0.66)
0.79
470/(470 + 128)
(0.75–0.82)
0.98
470/(470 + 10)
0.71
(0.47–1.07)
0.06
8/(8 + 128)
2.08
(1.21–3.56)
POC 1 h 50 g ≥ 7.2 mmol/L (129.6 mg/dL) 0.56
10/(10 + 8)
(0.34–0.75)
0.64
382/(382 + 216)
(0.60–0.67)
0.98
382/(382 + 8)
0.70
(0.41–1.17)
0.04
10/(10 + 216)
1.54
(1.00–2.36)
Venous FBG ≥ 5.1 (91.8 mg/dL) 0.78
14/(14 + 4)
(0.55–0.91)
1
598/(598 + 0)
(.99–1)
0.99
598/(598 + 4)
n/a 1
14/(14 + 0)
0.22
(0.09–0.53)
POC FBG ≥ 5.1 mmol/L (91.8 mg/dL) 0.33
6/(6 + 12)
(0.16–0.56)
0.95
567/(567 + 31)
(0.93–0.96)
0.98
567/(567 + 12)
0.70
(0.51–0.98)
0.16
6/(6 + 31)
6.43
(3.08–13.45)
POC 75 g OGTT 0.56
10/(10 + 8)
(0.34–0.75)
0.91
542/(542 + 56)
(0.88–0.93)
0.99
542/(542 + 8)
0.49
(0.29–0.82)
0.15
10/(10 + 56)
5.93
(3.66–9.61)
POC HbA1c ≥ 6.5% 0.22
4/(4 + 14)
(0.09–0.45)
0.99
592/(592 + 6)
(0.98–0.99)
0.98
592/(592 + 14)
0.79 (0.61–1.01) 0.4
4/(4 + 6)
22.15 (6.84–71.72)
Venous HbA1c ≥ 6.5% 0.11
2/(2 + 16)
(0.03–0.33)
0.99
591/(591 + 7)
(0.98–0.99)
0.97
591/(591 + 16)
0.90
(0.76–1.06)
0.22
2/(2 + 7)
9.49
(2.12–42.54)

TP true positives, FN false negatives, TN true negatives, FP false positives, HbAIc glycated hemoglobin, OGTT oral glucose tolerance test, POC point of care, RBG random blood glucose, FBG fasting blood glucose

aAll results were compared to the venous 75 g oral glucose tolerance test to demonstrate diagnostic accuracy